FDA Investigator Xiaoshi N Wang
Xiaoshi N Wang has conducted inspections on 2 sites in 1 countries as of 11 Dec 2023. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
2
Last Inspection Date:
11 Dec 2023
Investigator Role:
FDA Investigation Participant
Redica ID:
Countries of Inspections:
United States of America
FDA Investigators that have inspected at least one site in common with Xiaoshi N Wang:
Alice S Tsao,
Amy Devlin, PhD,
Anastasia G Lolas,
Andrea Siegel, PhD,
Anjali Shukla, PhD,
Bo Chi, PhD,
Brian A Roelofs,
Brian M Janelsins, PhD,
Brooke K Higgins,
Chaltu Nwakijra,
Dilip Devineni, PhD,
Donald C Obenhuber, PhD,
Dr. Zhihao Qiu (Peter), PhD,
Eric M Mueller, PharmD,
Frances Namuswe, PhD,
Hamet M Toure, PharmD MPH,
Ian L Mcwilliams,
Jee Chung, PhD,
Jennifer Swisher, PhD,
Jill J Tillman,
Jonathan W Chapman,
Joseph A Piechocki,
Joslyn K Brunelle, PhD,
Kalavati Suvarna, PhD,
Kathy Lee,
Lauren N Howard,
Laurie Graham,
LT Richard A Lyght,
Madushini Dharmasena, PhD,
Maria Gutierrez Lugo, PhD,
Mary E Farbman, PhD,
Massod Rahimi, PhD,
Michael Shanks, MS,
Michele L Glendenning,
Michele Perry Williams,
Monica E Murie,
Nebil A Oumer,
Rachel C Harrington,
Richard Ledwidge (nmi), PhD,
Robert J Ham,
Scott R Nichols, PhD,
Shadia Zaman, PhD,
Sidney B Priesmeyer,
Steven D Kehoe,
Steven E Bowen, PhD,
Tara L Greene,
Tara L King,
Teegan Dellibovi Ragheb, PhD,
Thuy T Nguyen, LCDR,
Warren J Lopicka,
Wendy G Tan, PhD,
Yongmin Liu,
Zhang Zhao, PhD
Xiaoshi N Wang's Documents
Publish Date | Document Type | Title |
---|---|---|
January, 2020 | EIR | Human Genome Sciences, Inc. - EIR, 2020-01-29 |
January, 2020 | FDA 483 Response | Human Genome Sciences, Inc. - Form 483R, 2020-02-18 |
November, 2023 | FDA 483 | Patheon Biologics LLC - Form 483, 2023-11-10 |
January, 2020 | FDA 483 | Human Genome Sciences, Inc. - Form 483, 2020-01-29 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more